All NewsBio/Pharma News
All PublicationsPharmTechPharmTech Europe
MarketplaceICH Q9 Revision: A Comprehensive Resource on Quality Risk ManagementPeer-Reviewed ResearchPharmTech ProductsPharma InsightsSponsored PodcastsSponsored VideosSponsored eBooksWhitepapers
Webcasts
All VideosAsk the ExpertBehind The HeadlinesBuy, Sell, HoldDrug Digest VideosDrug Solutions PodcastPeer ExchangeSexy ScienceTech Talk
Conference CoverageConference ListingEvents
Subscribe
AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
Spotlight -
  • Analytics
  • Dosage Forms
  • Drug Development
  • Manufacturing
  • Outsourcing
  • Quality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Webcasts
    • Subscribe
Advertisement

News

Article

November 20, 2023

Consent Decrees Entered Against Utah Supplement Manufacturer and Distributors

Author(s):

Susan Haigney

Consent decrees were issued against Evig LLC, of St. George, Utah, and Premium Production LLC, of St. George, Utah, for unapproved dietary supplements.

FDA announced on Nov. 16, 2023 that the US District Court for the District of Utah, Central Division, entered into consent decrees of permanent injunction with two dietary supplement companies, Evig LLC and Premium Production LLC, both based in St. George, Utah, and their chief operating officers.

Evig LLC and the company’s CEO, Douglas Lex Howard, distributes Balance of Nature products, which are marketed as dietary supplements that include labeling that renders them unapproved and misbranded drugs. “[FDA] has not approved Balance of Nature products for any use, despite the company’s claims that its products could be used to diagnose, cure, mitigate, treat, or prevent diseases such as cancer, heart disease, cirrhosis, diabetes, asthma, and COVID-19,” FDA stated in a press release. The agency says the company also violated current good manufacturing practice (CGMP) requirements.

The products were manufactured by Premium Production in violation of CGMPs, according to FDA, including “failing to establish ingredient and finished products specifications for identity, purity, strength, and composition, which rendered them adulterated dietary supplements.”

FDA sent both companies warning letters in 2019 after agency inspectors found CGMP violations during facility inspections at both companies’ facilities. Evig was warned Balance of Nature products were unapproved new and misbranded drugs. According to the agency, the companies failed to address the deviations, resulting in the injunctions.

“Products intended to treat or cure diseases require FDA approval,” said Principal Deputy Assistant Attorney General Brian M. Boynton, head of the Justice Department’s Civil Division, in a press release. “Dietary supplement makers also must abide by federal health and safety requirements. The Department will continue to work closely with FDA to stop the distribution of unapproved, adulterated, and misbranded dietary supplements.”

The two companies are prohibited from distributing or manufacturing products until they comply with CGMP and labeling regulations. Both companies must hire CGMP experts and submit documents to the agency demonstrating compliance and get FDA approval before resuming operations. Evig must also hire a labeling expert.

Source: FDA

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Related Videos
Dave A Miller, PhD, Chief Scientific Officer, AustinPx
Dave Miller, PhD, CSO, AustinPx
Related Content
Advertisement
AbbVie’s facility in Silicon Valley, South San Francisco, California, USA - June 7, 2023. AbbVie Inc. is an American pharmaceutical company. | Image Credit: © JHVEPhoto - stock.adobe.com
August 13th 2025

AbbVie to Invest $195 Million in US API Manufacturing

Patrick Lavery
Drug Solutions Podcast: Growth and Advancements in Fill/Finish
August 13th 2025

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com
August 13th 2025

Nxera’s New GLP-1 and GPCR-Targeted Drug Programs Aim to Advance Obesity and Metabolic Disorder Therapies

Feliza Mirasol
Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail
August 13th 2025

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
Pendulum used for readings and hypnotism swinging with motion blur | Image Credit: © fergregory - stock.adobe.com
August 13th 2025

Prasad Returns to Head FDA’s CBER

Christopher Cole
Pink-white and blue-white capsule pills with concept of precision medicine with nanotechnology, proteomics, and advanced artificial intelligence to enhance diagnostics and patient-specific solutions. | Image Credit: ©Artinun - stock.adobe.com
August 13th 2025

Personalized and Patient-Centric Administration of Oral Medicines

Cynthia A. Challener
Related Content
Advertisement
AbbVie’s facility in Silicon Valley, South San Francisco, California, USA - June 7, 2023. AbbVie Inc. is an American pharmaceutical company. | Image Credit: © JHVEPhoto - stock.adobe.com
August 13th 2025

AbbVie to Invest $195 Million in US API Manufacturing

Patrick Lavery
Drug Solutions Podcast: Growth and Advancements in Fill/Finish
August 13th 2025

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com
August 13th 2025

Nxera’s New GLP-1 and GPCR-Targeted Drug Programs Aim to Advance Obesity and Metabolic Disorder Therapies

Feliza Mirasol
Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail
August 13th 2025

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
Pendulum used for readings and hypnotism swinging with motion blur | Image Credit: © fergregory - stock.adobe.com
August 13th 2025

Prasad Returns to Head FDA’s CBER

Christopher Cole
Pink-white and blue-white capsule pills with concept of precision medicine with nanotechnology, proteomics, and advanced artificial intelligence to enhance diagnostics and patient-specific solutions. | Image Credit: ©Artinun - stock.adobe.com
August 13th 2025

Personalized and Patient-Centric Administration of Oral Medicines

Cynthia A. Challener
About Us
Advertise
Contact Us
Editorial Info
Editorial Advisory Board
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.